$PHVS

Nijdam Anna sold $56K of PHVS

Nijdam Anna (Principal Accounting Officer) sold 1,829 shares of Pharvaris N.V. (PHVS) at $30.60 on 2026-05-21.

Original reporting
SEC EDGAR · Nijdam Anna
Published May 26, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosure updates insider activity records and may influence short-term sentiment, but it does not constitute operational or financial guidance for PHVS.

02

Market read

Traders may monitor PHVS for additional insider transactions, but this single sale without company news is unlikely to be a standalone catalyst.

03

What to watch

No 10b5-1 plan is indicated, but absence of a plan in the snippet doesn’t confirm opportunistic selling; traders should watch for follow-on filings (buys/sells) and any upcoming PHVS catalysts.

Relevance 6/10Timing: Filed 2026-05-26 for a sale dated 2026-05-21; any market reaction would be most relevant on/after the filing date.

Background

This is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS), reported by a principal accounting officer.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

SEC Form 4 shows PHVS principal accounting officer Nijdam Anna sold 1,829 shares in an open-market transaction on 2026-05-21.

Expected impact

Likely minimal near-term impact; any reaction should fade unless followed by additional insider activity or company-specific catalysts.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying company news (earnings, trial, deal, or guidance).

Market effects

Limited read-across to biotech/clinical-stage peers; insider Form 4s are generally company-specific sentiment signals.

No clear regional spillover; event is US SEC disclosure for a foreign issuer.

Low—primarily affects local sentiment around PHVS rather than global biotech fundamentals.

Counterpoint

The sale could be for diversification or personal liquidity rather than a bearish view, especially since the article provides no context on motives or broader insider pattern.

Key entities

  • Pharvaris N.V.

    Subject of the Form 4 insider sale by a principal accounting officer.

  • Nijdam Anna

    Principal accounting officer who sold 1,829 shares of PHVS on 2026-05-21.

Related articles

MedAI 8/10

Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).